PACS Group (NYSE:PACS – Get Free Report) and GeneDx (NASDAQ:WGS – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.
Analyst Recommendations
This is a summary of current ratings and recommmendations for PACS Group and GeneDx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PACS Group | 0 | 2 | 5 | 0 | 2.71 |
| GeneDx | 1 | 1 | 6 | 0 | 2.63 |
PACS Group currently has a consensus target price of $48.00, suggesting a potential upside of 27.25%. GeneDx has a consensus target price of $96.43, suggesting a potential upside of 103.74%. Given GeneDx’s higher possible upside, analysts clearly believe GeneDx is more favorable than PACS Group.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| PACS Group | 4.49% | 26.47% | 4.36% |
| GeneDx | -17.58% | 9.15% | 5.21% |
Volatility & Risk
PACS Group has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500.
Valuation & Earnings
This table compares PACS Group and GeneDx”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PACS Group | $5.29 billion | 1.13 | $191.54 million | $1.56 | 24.18 |
| GeneDx | $442.68 million | 3.17 | -$21.02 million | ($2.68) | -17.66 |
PACS Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
61.7% of GeneDx shares are owned by institutional investors. 70.1% of PACS Group shares are owned by insiders. Comparatively, 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
PACS Group beats GeneDx on 8 of the 14 factors compared between the two stocks.
About PACS Group
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for PACS Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PACS Group and related companies with MarketBeat.com's FREE daily email newsletter.
